Upbeat earnings lift Wall Street as focus shifts to Fed
By Medha Singh and Devik Jain (Reuters) - U.S. stocks rose on Wednesday as a slew of positive earnings updates and hopes for assurances of continued support from the Federal Reserve overshadowed concerns about next steps for the government's coronavirus relief plan
By Medha Singh and Devik Jain
(Reuters) - U.S. stocks rose on Wednesday as a slew of positive earnings updates and hopes for assurances of continued support from the Federal Reserve overshadowed concerns about next steps for the government's coronavirus relief plan.
Advanced Micro Devices Inc jumped 12.4% after the chipmaker raised its full-year revenue forecast. Its shares were among the top boosts to the S&P 500 and Nasdaq.
The Philadelphia chip index rose 1.8%.
Starbucks Corp climbed 4.1% after the coffee chain said business was "steadily recovering" worldwide and it would return to profitability in the current quarter.
Of the 163 S&P 500 firms that have reported results, 79.1% have surpassed a low bar of quarterly profit expectations, according to Refinitiv IBES data.
Recent data pointed to a possible slowdown in business and hiring as several U.S. states reimposed restrictions after a spike in COVID-19 infections, while deaths in the country caused by the disease surpassed 150,000 on Wednesday.
Investors will keep a close watch on how the U.S. central bank addresses these economic risks at the end of a two-day policy meeting. The Fed's statement is expected at 2 p.m. ET (1800 GMT), which will be followed by Chair Jerome Powell's press conference.
"The consensus would be that Fed remains accommodative until we have a vaccine or a treatment for COVID-19, which would mean they are going to continue to provide liquidity which has essentially driven the market off the March low," said Nate Fischer, chief investment strategist at Strategic Wealth Partners in Cleveland.
Top Trump administration officials and Democratic congressional leaders tried to narrow stark differences over coronavirus aid on Wednesday, with no guarantees they can craft a compromise before some unemployment benefits expire.
At 12:43 p.m. ET, the Dow Jones Industrial Average was up 102.99 points, or 0.39%, at 26,482.27, the S&P 500 was up 29.70 points, or 0.92%, at 3,248.14. The Nasdaq Composite was up 113.14 points, or 1.09%, at 10,515.23.
Ten of the 11 major S&P sectors were higher with technology stocks providing the biggest boost to the S&P 500.
Boeing Co slipped 3.1% as it slashed production on its widebody programs and reported a bigger-than-expected loss due to the fallout from the pandemic.
General Electric Co fell 4.7% as it reported a wider-than-expected loss in the second quarter, but saw less cash outflow than estimated.
The chief executives of Amazon.com Inc, Facebook Inc, Apple Inc and Alphabet's Google are set to face a congressional hearing on antitrust on Wednesday, marking the first time appearing before lawmakers together.
All four companies are set to report results on Thursday.
Advancing issues outnumbered decliners for a 2.85-to-1 ratio on the NYSE and a 1.93-to-1 ratio on the Nasdaq.
The S&P index recorded 35 new 52-week highs and no new low, while the Nasdaq recorded 65 new highs and 12 new lows.
(Reporting by Medha Singh and Devik Jain in Bengaluru; Editing by Shounak Dasgupta)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
(Reuters) - Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion, the Wall Street Journal reported on Saturday, citing people familiar with the matter. A deal for Immunomedics, which last month reported positive data from a late-stage study for its breast-cancer drug, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2. Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment
SHANGHAI (Reuters) - China banned pork imports from Germany on Saturday after it confirmed its first case of African swine fever last week, in a move set to hit German producers and push up global prices as China's meat supplies tighten. China's ban on imports from its third largest supplier comes as the world's top meat buyer deals with an unprecedented pork shortage after its own epidemic of the deadly hog disease. The ban on Germany, which has supplied about 14% of China's pork imports so far this year, will push up demand for meat from other major suppliers like the United States and Spain, boosting global prices.
CAIRO (Reuters) - Libyan commander Khalifa Haftar has committed to ending a months-long blockade of oil facilities, the U.S.